JNJ stock performance?

Johnson & Johnson (JNJ) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Johnson & Johnson (JNJ) Stock Summary:

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.
126,000 Employees
Last Reported Date: 07/15/14
Founded in 1885
Last $101.27 USD
Change Today -0.53 / -0.52%
Volume 6.4M
As of 8:04 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - $106.74
52 Week Low
10/9/13 - $85.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
JNJ:US Advanced Stock Chart

johnson & johnson (JNJ) Related Bloomberg News

AIDS Cure Quest Advances as Cancer Drug Rouses Hidden HIV
Gilead Drug Combination Cures Hepatitis C in HIV Patients
Peterson’s Outsider Strategy for J&J Shakes Up Consumer
J&J’s Blockbuster Hepatitis C Sales Aren’t Enough
Yellen Testimony, China GDP, GM, JPMorgan: Week Ahead July 14-19

johnson & johnson (JNJ) Related News

The Excessively Networked VC Behind SherpaVentures
Rahm Emanuel's War on Drugs
China's State Planner Fines Contacts Lens Makers, Fights Terrorism
Winter Whining Turned Corporate Chiefs Into Meteorologists

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2014; Provides Earnings Guidance for the Full Year of 2014

Johnson & Johnson announced unaudited consolidated earnings results for the second quarter and six months of 2014. For the quarter, the company reported sales to customers of $19,495 million against $17,877 million a year ago. Earnings before provision for taxes on income were $5,626 million against $4,793 million a year ago. Net earnings were $4,326 million against $3,833 million a year ago. Diluted net earnings per share were $1.51 against $1.33 a year ago. Adjusted earnings before provision for taxes on income were $6,050 million against $5,359 million a year ago. Adjusted net earnings were $4,775 million against $4,289 million a year ago. Adjusted diluted net earnings per share were $1.66 against $1.48 a year ago. For the six months, the company reported sales to customers of $37,610 million against $35,382 million a year ago. Earnings before provision for taxes on income were $11,050 million against $9,054 million a year ago. Net earnings were $9,053 million against $7,330 million a year ago. Diluted net earnings per share were $3.15 against $2.55 a year ago. Adjusted earnings before provision for taxes on income were $11,610 million against $10,429 million a year ago. Adjusted net earnings were $9,201 million against $8,396 million a year ago. Adjusted diluted net earnings per share were $3.20 against $2.92 a year ago. The company increased its earnings guidance for full-year of 2014 to $5.85 to $5.92 per share. The company's guidance excludes the impact of special items.

Johnson & Johnson Agrees to Pay $4 Million to Settle Oregon Claims

Johnson & Johnson will pay Oregon $4 million to resolve deceptive marketing claims over recalled metal-on-metal hip implants in its first accord with any governmental unit involving the devices. While the sum is dwarfed by J&J's earlier settlement of patient lawsuits linked to the ASR hip, the agreement may lead the way for additional accords as federal and multistate probes continue into the company's sales of the device. Oregon is at the forefront of the investigations. A group of state attorneys general is investigating how the hips were marketed, while the U.S. Justice Department and the U.S. Attorney's Office in Massachusetts are probing whether the company made false claims or false statements about the devices to federal health care programs.

Johnson & Johnson Appoints D. Scott Davis as Director

Johnson & Johnson announced that its board of directors has appointed D. Scott Davis, Chief Executive Officer and Chairman of United Parcel Service Inc., as a Director of Johnson & Johnson. Mr. Davis will serve on the Audit Committee and the Regulatory, Compliance and Government Affairs Committee of the Board. Mr. Davis has presided over rapid growth in e-commerce delivery, international operations and supply chain and freight at UPS, since being named CEO in 2008. Mr. Davis will be retiring effective September 1, 2014, remaining as non-executive Chairman of the UPS board of directors. In addition to his leadership in public policy, Mr. Davis is on the Board of Honeywell International Inc. He serves as a trustee of the Annie E. Casey Foundation and is a member of The Carter Center Board of Councilors.

Johnson & Johnson financial resources

otc, otcbb, pinksheet, JNJ, ob Johnson & Johnson

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $101.27 USD -0.53

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.98 USD -0.48
Intel Corp $34.06 USD +0.36
International Business Machines Corp $190.85 USD -1.65
Roche Holding AG SFr.265.00 CHF +1.70
Procter & Gamble Co/The $80.28 USD -0.27

Industry Analysis


Industry Average

Valuation JNJ Industry Range
Price/Earnings 18.8x
Price/Sales 4.0x
Price/Book 3.8x
Price/Cash Flow 18.5x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Archieved Financial News About Johnson & Johnson

Drugmakers Seek End or Changes to U.S. Medication Naming Rules

Read article

J&J Recall Watch: Tylenol Cold Gelcaps Pulled

Read article

Is Donald Trump Buying Bank of America?

Keywords: Is Donald Trump Buying Bank of America?, intc,bac,blk,c,cat,dia,gld,jnj,pg
Quote:  I love real estate, but good real estate is very hard to get.”  Donald Trump explained that he bought stock in  Bank of America , Citigroup, Caterpillar, Intel, Johnson & Johnson, and Procter & Gamble.  Donald Trump also said, “I love these companies.  I’ve watched them for years and I’ve never owned stock in them.  I went out yesterday and said, look I’m not getting interest on CDs, so I went out and bought some stock.” Investors should ...
Read article

Best in Breed Dividend Stocks: Portfolio Check Up

Read article

Warren Buffett's Top 6 High-Yield Stocks: Beating the Broader Market So Far in 2011

Read article

Johnson & Johnson poised to outperform during recession, says Wells Fargo

Quote: Massachusetts AG sues Ortho-Mcneil over Risperdal marketingDrug manufacturer Ortho-McNeil-Janssen, a subsidiary of Johnson & Johnson, is being sued by the Attorney General of Massachusetts for illegally marketing Risperdal, an atypical antipsychotic medication. The lawsuit alleges that Janssen promoted the drug to treat elderly dementia and a number of uses in children and adolescents when these uses had not been shown to be safe and effective and had not been approved by t...
Read article

JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report

Read article

J&J Tentatively Agrees to Settle Risperdal Criminal Charge

Read article

If Fed Is Out of Bullets, Are Tax Cuts Only Option?

Keywords: Washington,United States,Treasurys,Treasury Department,Republicans,Political Leaders,Politics and Government,North America,Euro;EUR=X,Federal Budget (U.S.),Economy (U.S.),Democrats,Deficits,Debt,Currencies,Congress,Barack Obama,Bonds,Banking,Federal Reser
Read article

Johnson & Johnson: A Regal Dividend Stock Going Cheap

Read article

3 Dividend Powerhouses Selling at a Discount

Read article

Cramer's Watch List After Monday's Market Bloodbath

Read article

US approval of Roche melanoma drug may come early

Read article

S&P rating: Potential knock-on effects of downgrade

Keywords: S&P rating, downgrade, AAA, debt, debt ceiling, AA+, debt ceiling, debt rating, credit rating, debt, deficits,
Read article

A Look at Warren Buffett's 5 Best Bargain Stocks

Read article

Nexgen Artificial Knee Suits Targeting Zimmer Haunt Lawyers Seeking Payout

Read article

UPDATE 1-IFR-30-year debt too good to refuse with UST below 4%

Keywords: Ciara Linnane
Read article

RPT-UPDATE 1-Bayer rival Boehringer gets EU nod for Pradaxa pill

Keywords: United States
Read article

The 'Hold Forever Portfolio' Fallacy

Read article

UPDATE 3-Pfizer global drug sales fall, spark concern

Keywords: United States, Dave Zimmerman, Matthew Lewis, Michele Gershberg
Read article

You can still leave a comment about Johnson & Johnson JNJ

Besides Johnson & Johnson's Stock there is more great Microcap and Stock Market information available at